Mark Pegram
individual
About
Mark Pegram, MD, is a Stanford oncologist and breast-cancer researcher focused on HER2-positive disease, translational oncology, and early-phase clinical research. He serves in senior academic leadership roles at Stanford and is publicly listed on scientific advisory boards including Celcuity and Rubedo Life Sciences. His public profile is that of a medical and scientific opinion leader, not a fund manager or personal capital allocator.
Areas of interest
oncologybreast cancerHER2-targeted therapeuticsclinical researchprecision oncologytranslational medicinebiosimilarslongevitysenotherapeutics